Drug Profile
Umbilical cord mesenchymal stem cell therapy - Shanghai iCELL Biotechnology/Fujian Medical University
Alternative Names: UCMSCLatest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Shanghai iCELL Biotechnology
- Class Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory tract disorders
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for phase-I development in Respiratory-tract-disorders(In the elderly, In adults) in China
- 27 Jun 2019 Shanghai iCell plans a phase I/II trial for Inhaled lung injury in China (ChiCTR1900020919)
- 03 Nov 2016 Phase-I clinical trials in Respiratory tract disorders (In adults, In the elderly) in China (unspecified route) (NCT02961725)